Design, Synthesis and Anti Cancer Evaluation of novel 1, 3, 4-oxadiazoles

We designed and synthesized newer heterocyclic compounds with 1, 3, 4-thiadiazole, pyrimidine, and 1, 3, 4 -oxadiazole, with aimed to develop Histone Deacetylase (HDAC) inhibitors. The 1, 3, 4 - oxadiazole nucleus known for its diverse pharmacological properties and incorporating the thiadiazole and pyrimidine groups. The progress of synthesis was monitored using Thin Layer Chromatography (TLC). Further products were confirmed by IR, Mass spectra, melting point, IR and 1H-NMR. A molecular docking study indicated that synthesized compounds have great HDAC inhibitory activity. The biological evaluation of one derivative, compound VIII (a) was performed by the MTT assay, revealed notable anti-cancer activity. These findings suggest that the novel 1, 3, 4 - oxadiazole compounds could serve as promising candidates for futuristic development of anti-cancer agents.